


DB818

Cat. No.:	HY-122623		
CAS No.:	790241-43-9		
Molecular Formula:	C ₁₉ H ₁₆ N ₆ S		
Molecular Weight:	360.44		
Target:	Apoptosis		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	DB818 is a potent inhibitor of Homeobox A9 (HOXA9). HOXA9 is a transcription factor regulating haematopoiesis and leukaemia cell proliferation, involving in acute myeloid leukaemia (AML). DB818 inhibits AML cell lines growth, induces apoptosis ^[1] .
IC₅₀ & Target	Homeobox A9 (HOXA9) ^[1]
In Vivo	DB818 (12.5 mg/kg, 25 mg/kg; s.c.; once daily for 4 days) completely cures Parasitemia in mice infected with B. microti. at dose of 25 mg/kg, while cures 2/3 mice at 12.5 mg/kg ^[1] . DB818 results recrudescence occurring on mice around day 20 postinfection ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sonoda Y, et al. Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells. Anticancer Res. 2021 Apr;41(4):1841-1847.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA